Drug
Talimogene Laherparepvec
Drug Profile
| Therapeutic Class | Immunotherapy |
| Drug Class | Oncolytic virus |
| Group | Oncolytic virus |
| Mechanism of Action | Oncolytic virus |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Data on this page refer exclusively to patients treated with
Talimogene Laherparepvec combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Oncolytic virus group page.